RVTY News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

RV

Mkt Cap

$17.03B

Volume

1.04M

Next Earnings

November 3rd

Loading chart

RV

RVTYRevvity, Inc.

RVTY

Pay with—

Available Balance0.00

RV

Mkt Cap

$17.03B

Volume

1.04M

Next Earnings

November 3rd

Chart Financials Earnings News About Dividends Insider Filings

Thermo Fisher to Report Q3 Earnings: What's in the Cards?Thermo Fisher Scientific is set to report Q3 2026 results on October 21, with consensus estimates projecting 7.1% revenue growth to $11.91B and 10.5% EPS growth to $6.40. The company's Life Sciences Solutions and Laboratory Products segments are expected to drive growth at 10.1% and 9.8% respectively, supported by recent product innovations. However, Specialty Diagnostics revenues are projected to decline 3% following the sale of its microbiology business to Astorg for $1.075 billion.Zacks Investment Research · Oct 13, 2026

Revvity (RVTY) Upgraded to Buy: What Does It Mean for the Stock?Revvity (RVTY), a maker of scientific instruments, has been upgraded to Zacks Rank #2 (Buy) due to rising earnings estimate revisions over the past three months. The upgrade reflects positive momentum in the company's earnings outlook, which historically correlates with near-term stock price increases. The company is expected to earn $5.36 per share for fiscal year 2026.Zacks Investment Research · Oct 2, 2026

North America Non-Viral Transfection Reagents Market Forecast to 2035 | Cell and Gene Therapy Demand Drives 8.5% CAGR and a USD 0.70 Billion OpportunityThe North America non-viral transfection reagents market is projected to grow from USD 0.34 billion in 2026 to USD 0.70 billion by 2035, representing an 8.5% CAGR. Growth is driven by rising investment in cell and gene therapy, increasing demand for nucleic acid-based treatments, and advances in scalable, low-toxicity delivery technologies. Physical methods like electroporation currently lead the market, while chemical delivery vectors are expected to show fastest growth. Clinical applications are projected to register the highest CAGR as cell and gene therapy programs advance.GlobeNewswire Inc. · Sep 30, 2026

Here's Why You Should Retain Revvity Stock in Your Portfolio for NowRevvity (RVTY) is rated a Hold with strong growth potential across diagnostics, life sciences, and scientific informatics. The company benefits from AI-driven demand, the planned Human Cell Design acquisition, and solid diagnostics growth (11% organic revenue increase in Q2). However, challenges include China divestiture uncertainty, uneven academic funding, and margin pressure from non-recurring tariff benefits. The stock has outperformed the broader market with a 56.1% year-to-date gain.Zacks Investment Research · Sep 29, 2026

Global Alzheimer’s Disease Biomarker Market Poised for Phenomenal Expansion at a Growth Rate of ~9% by 2034 | DelveInsightThe global Alzheimer's disease biomarker market is projected to grow from USD 2.2 billion in 2025 to USD 4.7 billion by 2034, driven by rising disease prevalence, aging populations, and advancements in blood-based biomarkers like phosphorylated tau and amyloid-beta assays. North America leads the market with 41% share, while Asia-Pacific is the fastest-growing region. Recent FDA clearances and expanded laboratory testing availability are accelerating market adoption.GlobeNewswire Inc. · Sep 22, 2026

Strength Seen in Revvity (RVTY): Can Its 9.1% Jump Turn into More Strength?Revvity shares surged 9.1% to $140.19 following upbeat commentary on AI-driven demand for research tools, improved order backlog, and a planned acquisition of Human Cell Design. The company expects quarterly EPS of $1.28 (+8.5% YoY) and revenues of $702.56M (+0.5% YoY). However, consensus EPS estimates have been marginally revised lower over the past 30 days, which could limit further price appreciation.Zacks Investment Research · Sep 16, 2026

Epigenetics Market Intelligence Report 2026: Strong Demand from Oncology, Precision Medicine, Pharmaceutical Research, and Liquid-Biopsy DevelopmentThe global epigenetics market is estimated at USD 2.70 billion in 2025 and projected to reach USD 8.30 billion by 2034, expanding at a CAGR of 13.3%. Growth is driven by rising cancer burden, precision medicine adoption, liquid-biopsy development, and advances in sequencing technologies. DNA methylation dominates the technology segment at 48% market share, while kits and reagents lead products at 41%. Oncology represents the largest application at 60%, with pharmaceutical and biotech companies as the primary end-users at 44% market share. North America leads with 43% global revenue, while Asia-Pacific is the fastest-growing region.GlobeNewswire Inc. · Sep 9, 2026

Global Multiplex Assays Market 2026 Edition - Consumables Dominate Multiplex Assays with 68% Market ShareThe global multiplex assays market is projected to grow from US$6.8 billion in 2025 to US$12.4 billion by 2030, at a 12.8% CAGR. North America leads with 34% market share, while Asia Pacific is the fastest-growing region at 15.5% CAGR. Consumables dominate with 68% market share, and protein multiplex assays hold 42%. Growth is driven by precision medicine, companion diagnostics, and laboratory automation.GlobeNewswire Inc. · Sep 4, 2026

Global Laboratory Equipment Services Market Size/Share Worth USD 62.83 Billion by 2035 at a 8% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)The global laboratory equipment services market is projected to grow from USD 28.94 billion in 2025 to USD 62.83 billion by 2035, at a CAGR of 8%. Growth is driven by increased R&D investments in life sciences, stricter regulatory compliance requirements, expansion of biopharma facilities, and adoption of IoT-enhanced predictive maintenance technologies. Repair and maintenance services represent the largest market segment, with North America dominating and Asia Pacific showing the fastest growth.GlobeNewswire Inc. · Jun 24, 2026

Cord Blood Banking Services Market: USD 49.85 Bn Opportunity to 2031 Led by Stem Cell Advancements, Says Mordor IntelligenceThe global cord blood banking services market is projected to grow from USD 33.85 billion in 2025 to USD 49.85 billion by 2031, with a CAGR of 6.84%. Growth is driven by increasing awareness of stem cell therapies, advancements in regenerative medicine, and expanding clinical applications in treating hematological and genetic disorders. North America leads with 39.54% market share, while Asia-Pacific emerges as a high-growth region.GlobeNewswire Inc. · Feb 27, 2026

to start trading

RV

RVTYRevvity, Inc.

RVTY

Pay with—

Available Balance0.00

Your PositionYou don't own any RVTY yet.

Related Tickers

Earnings

Dividends

Ex Oct 23

Amount$0.0700

PaysNov 13

Last · Jul 17Quarterly

Amount$0.0700

Yield0.14%

Annual$0.21